cell based therapy
Recently Published Documents


TOTAL DOCUMENTS

1439
(FIVE YEARS 594)

H-INDEX

60
(FIVE YEARS 13)

2022 ◽  
Vol 23 (2) ◽  
pp. 863
Author(s):  
Alessia Gallo ◽  
Nicola Cuscino ◽  
Flavia Contino ◽  
Matteo Bulati ◽  
Mariangela Pampalone ◽  
...  

Mesenchymal stromal/stem cells (MSCs) are believed to function in vivo as a homeostatic tool that shows therapeutic properties for tissue repair/regeneration. Conventionally, these cells are expanded in two-dimensional (2D) cultures, and, in that case, MSCs undergo genotypic/phenotypic changes resulting in a loss of their therapeutic capabilities. Moreover, several clinical trials using MSCs have shown controversial results with moderate/insufficient therapeutic responses. Different priming methods were tested to improve MSC effects, and three-dimensional (3D) culturing techniques were also examined. MSC spheroids display increased therapeutic properties, and, in this context, it is crucial to understand molecular changes underlying spheroid generation. To address these limitations, we performed RNA-seq on human amnion-derived MSCs (hAMSCs) cultured in both 2D and 3D conditions and examined the transcriptome changes associated with hAMSC spheroid formation. We found a large number of 3D culture-sensitive genes and identified selected genes related to 3D hAMSC therapeutic effects. In particular, we observed that these genes can regulate proliferation/differentiation, as well as immunomodulatory and angiogenic processes. We validated RNA-seq results by qRT-PCR and methylome analysis and investigation of secreted factors. Overall, our results showed that hAMSC spheroid culture represents a promising approach to cell-based therapy that could significantly impact hAMSC application in the field of regenerative medicine.


F1000Research ◽  
2022 ◽  
Vol 11 ◽  
pp. 38
Author(s):  
Mikhail Raevskiy ◽  
Anna Kondrashina ◽  
Yulia Medvedeva

Identification of transcription factors (TFs) that could induce and direct cell conversion remains a challenge. Though several hundreds of TFs are usually transcribed in each cell type, the identity of a cell is controlled and can be achieved through the ectopic overexpression of only a small subset of so-called core TFs. Currently, the experimental identification of the core TFs for a broad spectrum of cell types remains challenging. Computational solutions to this problem would provide a better understanding of the mechanisms controlling cell identity during natural embryonic or malignant development, as well as give a foundation for cell-based therapy. Herein, we propose a computational approach based on over-enrichment of transcription factors binding sites (TFBS) in differentially accessible chromatin regions that could identify the potential core TFs for a variety of primary human cells involved in hematopoiesis. Our approach enables the integration of both transcriptomic (single-cell RNA sequencing, scRNA-seq) and epigenenomic (single-cell assay for transposable-accessible chromatin, scATAC-seq) data at the single-cell resolution to search for core TFs, and can be scalable to predict subsets of core TFs and their role in a given conversion between cells.


2022 ◽  
Vol 12 ◽  
Author(s):  
Andrea Henriques-Pons ◽  
Daniela Gois Beghini ◽  
Vanessa dos Santos Silva ◽  
Samuel Iwao Horita ◽  
Fabrício Alves Barbosa da Silva

Mesenchymal stem cells (MSCs) are multipotent adult stem cells present in virtually all tissues; they have potent self-renewal capacity and differentiate into multiple cell types. For many reasons, these cells are a promising therapeutic alternative to treat patients with severe COVID-19 and pulmonary post-COVID sequelae. These cells are not only essential for tissue regeneration; they can also alter the pulmonary environment through the paracrine secretion of several mediators. They can control or promote inflammation, induce other stem cells differentiation, restrain the virus load, and much more. In this work, we performed single-cell RNA-seq data analysis of MSCs in bronchoalveolar lavage samples from control individuals and COVID-19 patients with mild and severe clinical conditions. When we compared samples from mild cases with control individuals, most genes transcriptionally upregulated in COVID-19 were involved in cell proliferation. However, a new set of genes with distinct biological functions was upregulated when we compared severely affected with mild COVID-19 patients. In this analysis, the cells upregulated genes related to cell dispersion/migration and induced the γ-activated sequence (GAS) genes, probably triggered by IFNGR1 and IFNGR2. Then, IRF-1 was upregulated, one of the GAS target genes, leading to the interferon-stimulated response (ISR) and the overexpression of many signature target genes. The MSCs also upregulated genes involved in the mesenchymal-epithelial transition, virus control, cell chemotaxis, and used the cytoplasmic RNA danger sensors RIG-1, MDA5, and PKR. In a non-comparative analysis, we observed that MSCs from severe cases do not express many NF-κB upstream receptors, such as Toll-like (TLRs) TLR-3, -7, and -8; tumor necrosis factor (TNFR1 or TNFR2), RANK, CD40, and IL-1R1. Indeed, many NF-κB inhibitors were upregulated, including PPP2CB, OPTN, NFKBIA, and FHL2, suggesting that MSCs do not play a role in the “cytokine storm” observed. Therefore, lung MSCs in COVID-19 sense immune danger and act protectively in concert with the pulmonary environment, confirming their therapeutic potential in cell-based therapy for COVID-19. The transcription of MSCs senescence markers is discussed.


Cells ◽  
2022 ◽  
Vol 11 (2) ◽  
pp. 221
Author(s):  
Adriana de Cássia Ortiz ◽  
Simone Ortiz Moura Fideles ◽  
Karina Torres Pomini ◽  
Márcia Zilioli Bellini ◽  
Eliana de Souza Bastos Mazuqueli Pereira ◽  
...  

Cell-based therapy is a promising treatment to favor tissue healing through less invasive strategies. Mesenchymal stem cells (MSCs) highlighted as potential candidates due to their angiogenic, anti-apoptotic and immunomodulatory properties, in addition to their ability to differentiate into several specialized cell lines. Cells can be carried through a biological delivery system, such as fibrin glue, which acts as a temporary matrix that favors cell-matrix interactions and allows local and paracrine functions of MSCs. Thus, the aim of this systematic review was to evaluate the potential of fibrin glue combined with MSCs in nerve regeneration. The bibliographic search was performed in the PubMed/MEDLINE, Web of Science and Embase databases, using the descriptors (“fibrin sealant” OR “fibrin glue”) AND “stem cells” AND “nerve regeneration”, considering articles published until 2021. To compose this review, 13 in vivo studies were selected, according to the eligibility criteria. MSCs favored axonal regeneration, remyelination of nerve fibers, as well as promoted an increase in the number of myelinated fibers, myelin sheath thickness, number of axons and expression of growth factors, with significant improvement in motor function recovery. This systematic review showed clear evidence that fibrin glue combined with MSCs has the potential to regenerate nervous system lesions.


2022 ◽  
Vol 13 (1) ◽  
Author(s):  
Xiao-Na Xiang ◽  
Si-Yi Zhu ◽  
Hong-Chen He ◽  
Xi Yu ◽  
Yang Xu ◽  
...  

AbstractOsteoarthritis, as a degenerative disease, is a common problem and results in high socioeconomic costs and rates of disability. The most commonly affected joint is the knee and characterized by progressive destruction of articular cartilage, loss of extracellular matrix, and progressive inflammation. Mesenchymal stromal cell (MSC)-based therapy has been explored as a new regenerative treatment for knee osteoarthritis in recent years. However, the detailed functions of MSC-based therapy and related mechanism, especially of cartilage regeneration, have not been explained. Hence, this review summarized how to choose, authenticate, and culture different origins of MSCs and derived exosomes. Moreover, clinical application and the latest mechanistical findings of MSC-based therapy in cartilage regeneration were also demonstrated.


2022 ◽  
pp. 578-590
Author(s):  
G. Guarnieri ◽  
E. Sarchielli ◽  
P. Gallina ◽  
A. Morelli

2022 ◽  
Author(s):  
Isha Goel ◽  
Makoto Noiri ◽  
Yuka Yamauchi ◽  
Koichi Kato ◽  
Ung-il Chung ◽  
...  

Cell-based therapy has been used to treat stroke related disorders, which have no treatment options available 4.5 hours after onset. Although the administration of tissue plasminogen activator and mechanical thrombectomy...


Blood Reviews ◽  
2022 ◽  
pp. 100925
Author(s):  
Jennifer N. Leibovitch ◽  
Ajay V. Tambe ◽  
Emanuela Cimpeanu ◽  
Maria Poplawska ◽  
Firas Jafri ◽  
...  

2021 ◽  
Vol 11 (2) ◽  
pp. 142-145
Author(s):  
Pradeep V. Mahajan ◽  
Swetha Subramanian ◽  
Siddhesh C. Parab ◽  
Sanskruti Mahajan

Drug-resistant epilepsy (DRE) is a global public health problem. This category includes patients who continue to experience seizures despite long-term anti-epileptic medications. DRE can lead to severe disability and morbidity in older children and adults and is associated with increased risk of mortality than the general population. This report describes the case of a 15-year-old male patient with DRE successfully managed with autologous cell-based and hyperbaric oxygen therapy. The patient underwent two sessions of cell-based therapy consisting of cells derived from the bone marrow, adipose tissue, and peripheral blood followed by neuro-physiotherapy and oxygen therapy. Post-treatment, the patient experienced decrease in the frequency of seizures and reduction in the dosage of anti-epileptic medications. Electroencephalogram taken one year after the therapy revealed improvement in seizure activity. The outcomes in this case may be considered a preliminary finding in formulating more robust treatment strategies using cell-based therapy for DRE.


Sign in / Sign up

Export Citation Format

Share Document